DMAC Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (20 mai 2024 @ 22:00):

Stats
Dagens volum	6 661.00
Gjennomsnittsvolum	40 527.00
Markedsverdi	116.17M
EPS	$0 ( 2024-05-20 )
Neste inntjeningsdato	( $-0.160 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.10
ATR14	$0.0170 (0.56%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-22	Lorianne Masuoka K.	Buy	285 000	Stock option (right to buy)
2024-01-22	Lorianne Masuoka K.	Buy	0
2024-01-02	Semba Charles Pauling	Buy	9 375	Voting Common Shares, no par value per share
2024-01-02	Kuntz Richard	Buy	14 285	Voting Common Shares, no par value per share
2024-01-02	Pilnik Richard D.	Buy	30 357	Voting Common Shares, no par value per share

INSIDER POWER
54.04
Last 91 transactions
Buy: 8 059 792 \| Sell: 2 870 847

DiaMedica Therapeutics Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

DiaMedica Therapeutics Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-30 000.00 (0.00 %)
EPS:	$-0.600

FY	2023
Omsetning:	$0
Bruttogevinst:	$-30 000.00 (0.00 %)
EPS:	$-0.600

FY	2022
Omsetning:	$0
Bruttogevinst:	$-25 000.00 (0.00 %)
EPS:	$-0.520

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.650

Financial Reports:

No articles found.

DiaMedica Therapeutics Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

DiaMedica Therapeutics

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.